Share Name Share Symbol Market Type Share ISIN Share Description
Heiq Plc LSE:HEIQ London Ordinary Share GB00BN2CJ299 ORD GBP0.30
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.25 -0.71% 35.00 34.50 36.00 35.50 35.25 35.25 59,445 16:35:26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 36.9 5.1 3.1 10.3 44

Heiq Share Discussion Threads

Showing 1 to 9 of 675 messages
Chat Pages: Latest  3  2  1
Nice finish today, but we are still flying well under the radar.

HeiQ Plc

Concludes acquisition of majority stake in Spanish medical device manufacturer

HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has completed the acquisition of a majority stake in a leading Spanish mask manufacturer, MasFabEs, further to entering into a joint venture outlined in the Company's Prospectus. The manufacturer has been renamed HeiQ Medica S.L. and will manufacture medical devices with HeiQ's cutting-edge textile technologies.

MasFabEs has already been producing OTC (over the counter) medical device Type IIR surgical masks (certified for use in a close clinical environments), enhanced with HeiQ Viroblock technology, since the beginning of the pandemic. To date, over 1 billion community face coverings as well as medical masks enhanced with HeiQ Viroblock technology have been sold and the technology is already being used by more than 150 major mask brands such as Burberry.

The Company continues to experience strong demand for surgical masks which benefit from the extra protection provided by its Swiss Technology Award-winning HeiQ Viroblock technology. With a maximum production capacity of 15 million masks per month, enough to cover the needs of entire Switzerland with two masks a day, this acquisition will provide HeiQ with more control over the manufacture of its products. It will also provide the Company with an ideal base from which to establish an R&D hub for medical devices in Europe. Bulk order supply will be prioritised for institutions in the medical and healthcare sectors, such as hospitals, clinics, pharmacies and care homes. The masks will also be available on HeiQ's direct to consumer webshop.

HeiQ co-founder and CEO Carlo Centonze said:

"As a leading, profitable player in the $10 billion antimicrobial market, this manufacturing capability will ensure that we are well positioned to meet the strong on-going demand that we are experiencing for our products. The acquisition is in line with our stated strategy to deliver shareholder value by building on the significant momentum achieved by HeiQ Viroblock while also growing other innovations within our core product portfolio. The pandemic has changed our behaviour for good. Following the SARS epidemic in Asia in 2003, all medical and healthcare workers now use face masks daily in this region and we are confident that this practice will continue worldwide even when the Covid-19 pandemic is under control.

"The third pillar of our growth strategy is focused on launching new high margin innovations which serve high growth markets. We are working on a range of exciting technologies, including a new antimicrobial technology with our long standing Australian partner Xefco, as well as our graphene membrane innovation. We look forward to sharing news of a number of exciting advancements ongoing within our R&D pipeline in the coming months."

Pedro Herranz, Co-founder and General Manager of MasFabEs, said:

"As a company that was founded expressly to provide "made in Spain" products, hence the name MasFabEs (Mascarillas de FabricaciĆ³n EspaƱola), we were already producing HeiQ Viroblock powered masks and enjoyed an excellent relationship with HeiQ. Their majority participation, distribution reach and their plans for applying their materials innovations to medical devices were received with open arms and we are excited about future developments."

And off we go to the races.
I asked Transact yesterday morning at 8am to add HEIQ to their platform. They emailed me back at 1120 to say it was there. Cracking service as ever.
Hi all. Short TV clip with HEIQ Founders about the company:

They said they'll email me when it's added. In the meantime, there's an interesting presentation on their website (and prospectus).

I was just about to ask same question also had problem with IG
Had to contact IG to ask them why they weren't quoting it - said it will take 1-3 days to get it added! Would have thought in this day and age, it should be 8am on day of listing.
Introduction and placing today @ 112p

HeiQ is a leader in textile innovation creating some of the most effective, durable and high-performance textile effects in the market today.

Interesting aspect is HeiQ Viroblock NPJ03 tested effective against SARS-CoV-2 (COVID-19). HeiQ Viroblock NPJ03 is an antiviral and antibacterial textile treatment – a unique combination of silver and vesicle technologies designed to significantly reduce viral and bacterial infectivity on treated surfaces.

rat attack
Chat Pages: Latest  3  2  1
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230127 04:29:46